Advent International Corporation
75 State Street
Boston, MA 02109
USA
Telephone: +1.617.951.9400
Fax: +1.617.951.0566
Email: jfisherman@adventinternational.com
Dr. Jason Fisherman joined Advent in 1994. Prior to Advent, Dr. Fisherman was senior director of medical research at Enzon, where he managed clinical programs in oncology, genetic diseases and blood substitutes. Previously, at the National Cancer Institute, he was responsible for developing a portfolio of anticancer drugs, including Taxol. While a research fellow at Dana Farber Cancer Institute, he focused on the regulation of gene transcription and molecular oncology.
Dr. Fisherman has led or co-led Advent's investments in over 20 companies, including Achillion Pharmaceuticals, Anadys Pharmaceuticals, Array BioPharma (Nasdaq: ARRY), Cellzome, Crucell (Nasdaq: CRXL; Euronext), Cubist Pharmaceuticals (Nasdaq: CBST), CV Therapeutics (Nasdaq: CVTX), deCODE genetics (Nasdaq: DCGN), EPIX Medical (Nasdaq: EPIX), Exelixis (Nasdaq: EXEL), ILEX Oncology (Nasdaq: IXLO), Neurogenetics, Oridion Systems (NSWX: ORIDN) and Telik (Nasdaq: TELK).
He received a BA in molecular biophysics and biochemistry from Yale, an MD from the University of Pennsylvania and an MBA from the Wharton School of the University of Pennsylvania. He is board certified in internal medicine and medical oncology.
Dr. Fisherman is currently a member of the board of directors of Achillion Pharmaceuticals, Inc., Anadys Pharmaceuticals, Inc., Cellzome, Inc., Exelixis, Inc., ILEX Oncology, Inc., Neurogenetics, Inc., and Oridion Systems Ltd.